HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Perrigo To Launch UK Private-Label Viagra Connect Competitor

Executive Summary

Perrigo is launching in the UK an OTC sildenafil generic to compete with Pfizer's erectile dysfunction drug Viagra Connect. 

You may also be interested in...



Futura Launches Eroxon Erectile Dysfunction Gel In Europe, US Launch Delayed Until Q2 2023

European consumers can now buy Futura Medical's Eroxon erectile dysfunction gel without a prescription online, and in person via Belgian pharmacies. Further country launches, supported by advertising and promotional campaigns, remain on track during the coming months, Futura says. However, the US launch, expected for Q1 this year, has been delayed while the firm answers questions posed by the FDA.

UK Cialis Rx-To-OTC Switch World-First For Sanofi, H2 2023 Launch Planned

The UK is the first country to allow OTC access to Sanofi's tadalafil-based erectile dysfunction drug Cialis following a successful switch. Approved as a pharmacy medicine, Sanofi will launch Cialis Together in the second half of the year. Cialis will compete against Viatris' sildenafil-based Viagra Connect in the men's sexual health and wellness category, which has seen a proliferation of products in recent months.

German Rx-To-OTC Switch Committee To Consider Sildenafil Reclassification

Rx-to-OTC switches of sildenafil and xylometazoline and ipratropium bromide combinations are on the cards for January's meeting of the German Expert Committee for Prescription.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

RS149690

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel